Given the critical role of GLUT1 in the maintenance of the self-renewal capacity of the CSCs, we next asked if we could inhibit, similarly to the self-renewal capacity, the tumor-initiating capacity of the CSCs by targeting GLUT1 in vitro, and from a therapeutic point of view, in vivo as well. Here, SLC2A1 is linked to neoplasm.